The OIDD Program, Lilly's Open Innovation platform

Abstract

The drug discovery process is continuously evolving and pharmaceutical companies have changed the strategies for effective collaboration in research. The current trend is focused on external innovation and the interactions between academic and public sectors have been gradually increased. Many companies have implemented Open Innovation strategies to attract external talent, share knowledge and leverage synergies creating value. In this ecosystem, the Lilly OIDD (Open Innovation Drug Discovery) program offers a variety of engagement modes to the affiliated investigators and has had an excellent acceptance globally with 800 participants and 53.000 compounds tested.